Esperion Therapeutics Inc
NASDAQ:ESPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Esperion Therapeutics Inc
Cost of Revenue
Esperion Therapeutics Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Esperion Therapeutics Inc
NASDAQ:ESPR
|
Cost of Revenue
-$129.2m
|
CAGR 3-Years
-69%
|
CAGR 5-Years
-122%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cost of Revenue
-$30.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cost of Revenue
-$84.5m
|
CAGR 3-Years
80%
|
CAGR 5-Years
62%
|
CAGR 10-Years
32%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cost of Revenue
-$15.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cost of Revenue
-$14.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cost of Revenue
-$12.4B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-9%
|
|
Esperion Therapeutics Inc
Glance View
Esperion Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Ann Arbor, Michigan and currently employs 218 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The firm's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
See Also
What is Esperion Therapeutics Inc's Cost of Revenue?
Cost of Revenue
-129.2m
USD
Based on the financial report for Dec 31, 2025, Esperion Therapeutics Inc's Cost of Revenue amounts to -129.2m USD.
What is Esperion Therapeutics Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-122%
Over the last year, the Cost of Revenue growth was -88%. The average annual Cost of Revenue growth rates for Esperion Therapeutics Inc have been -69% over the past three years , -122% over the past five years .
